The Challenge of Prostate MRI
Prostate cancer can be difficult to characterize. Tumor heterogeneity means that disease within the same gland, and even within the same tumor, may demonstrate different levels of aggressiveness. That complexity carries into imaging and biopsy, making high-quality MRI and careful interpretation important.
PI-RADS v2.1 gives us a common language for prostate MRI, but it does not eliminate the challenge. PI-RADS 3 lesions remain difficult because they occupy the middle ground where we are trying to avoid both unnecessary biopsy and missed clinically significant cancer. Peripheral-zone and transition-zone lesions are also assessed differently, requiring us to integrate T2-weighted imaging, diffusion-weighted imaging, ADC maps, and, when applicable, dynamic contrast enhancement.1
AI as a “Backseat Pilot”
This is where I believe artificial intelligence can add value. AI-supported prostate applications can segment the gland and its zones, identify suspicious regions of interest, evaluate enhancement kinetics, and provide visual support for PI-RADS assessment.2 The objective is not to replace the radiologist. AI can serve as a second set of eyes and help us work through multiple imaging findings more consistently.
My approach is to interpret the conventional MRI first and reach my own impression before reviewing the AI output. I think of AI as a “backseat pilot.” It may confirm what I have seen, but it may also direct my attention to something that deserves another look.
What the Cases Show
One case demonstrates the importance of looking beyond the initial abnormality. A subtle lesion near the junction of the transition zone and anterior fibromuscular stroma raised concern on conventional MRI. AI analysis also highlighted a second lesion near the peripheral-zone/transition-zone junction that was less apparent on the conventional images. Targeted biopsy confirmed cancer (Figure 1).
Figure 1.
The “second corner lesion.” Conventional multiparametric MRI demonstrates a subtle lesion, while AI-assisted segmentation and heat-map analysis highlight an additional suspicious focus that was subsequently confirmed on biopsy.
Size can present a different challenge. In another case, a relatively large lesion in the anterior fibromuscular stroma was not immediately obvious on conventional imaging. AI analysis more clearly highlighted the diffusion restriction and ADC abnormality associated with the lesion (Figure 2).
Figure 2.
The large transition-zone/anterior fibromuscular stroma lesion. Although the abnormality is subtle on conventional MRI, AI-supported analysis emphasizes the associated diffusion restriction and ADC abnormality.
Transition-zone lesions present another interpretive challenge because of the underlying heterogeneity of the gland. In a biopsy-proven transition-zone cancer, the lesion was subtle on conventional imaging, while AI helped highlight the diffusion restriction and ADC signal loss (Figure 3).
Figure 3.
The subtle transition-zone lesion. AI-assisted analysis highlights diffusion restriction and ADC signal loss in a biopsy-proven cancer that is difficult to appreciate prospectively on conventional imaging.
These cases reinforce an important point. AI is most useful when it complements, rather than substitutes for, experience. A radiologist who has interpreted a thousand prostate MR examinations will approach a subtle lesion differently from someone early in training. Based on my observations, AI may help less-experienced readers by consistently drawing attention to suspicious imaging patterns.
Detection Must Lead to Accurate Targeting
Finding a suspicious lesion is only part of the process. If we cannot accurately biopsy the abnormality, the imaging has limited clinical value. MRI/ultrasound fusion biopsy allows us to transfer MRI-defined targets to ultrasound-guided biopsy and sample the region of concern directly. Because prostate cancer is heterogeneous and multifocal disease is common, targeted biopsy should also be considered in the context of appropriate gland sampling.
Our early real-world assessment of prostate AI included 25 sequential patients with biopsy-proven clinically significant disease and 46 lesions. In that small retrospective experience, AI identified all 46 lesions, including nine that had been undercalled on the radiologic reads, with four false-positive findings. These results should be interpreted cautiously. This was a limited practical validation exercise, not a definitive clinical trial, and in my subsequent experience false-negative patterns do occur.
The larger lesson is not that AI is infallible. High-quality prostate MRI, experienced
interpretation, AI-assisted review, and accurately targeted fusion biopsy can work together as part of a more consistent diagnostic pathway. The goal remains straightforward: detect the suspicious lesion, characterize it appropriately, and make sure the biopsy reaches the target.
References
1. American College of Radiology, European Society of Urogenital Radiology, AdMeTech Foundation. PI-RADS: Prostate Imaging–Reporting and Data System. Version 2.1. American College of Radiology; 2019. Accessed September 2, 2026.
2. Canellas R, Kohli MD, Westphalen AC. The evidence for using artificial intelligence to enhance prostate cancer MR imaging. Curr Oncol Rep. 2023;25(4):243-250. doi:10.1007/s11912-023-01371-y.
3. Wei JT, Barocas D, Carlsson S, et al. Early Detection of Prostate Cancer: AUA/SUO Guideline Part II: Considerations for a Prostate Biopsy. J Urol. 2023;210(1):54-63. doi:10.1097/JU.0000000000003492.